Kardigan Stock
Kardigan, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Tassos Gianakakos
- Employees
- 241
- Market cap
- $1.2 B
- IPO
- 18/06/2026
Kardigan, Inc. is a clinical-stage precision therapeutics company operating within the Healthcare sector and the Biotechnology industry. Headquartered in Princeton, USA, the company is led by CEO Tassos Gianakakos. Kardigan, Inc. focuses on developing medicines that target the root cause of specific cardiovascular…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Kardigan stock: price history
1D
-6.1%
1W
-11.2%
1M
-24.7%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
Not enough history for an assessment
Ask the agents about Kardigan
Analyst assessment of Kardigan
PRICE TARGET LOW
US$25.00
CONSENSUS
US$34.00
MEDIAN
US$37.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 25/08/2026
Kardigan stock metrics
P/E
-6.09
P/B
1.98
EV/EBITDA
-6.12
RETURN ON EQUITY
-18.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.9%
FLOAT SHARES
51,758,973
AVG. DAILY VOLUME (30D)
826,422
Insider transactions (SEC)
PERCEPTIVE ADVISORS LLC
ARCH Venture Partners XIII, LLC
BERNS PAUL L
HRTG GPE, LLC
Edelberg Jay
Institutional holders
Comparable stocks
Frequently asked questions about Kardigan stock
What does Kardigan do?
Kardigan, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Tassos Gianakakos, the company employs around 241 people.
The IPO was on 18/06/2026; the stock trades on NASDAQ under the ticker KARD.
What do analysts say about Kardigan stock?
1 analysts rate the stock, the consensus is Buy (as of 25/08/2026).
The average price target is US$34.00, ranging from US$25.00 to US$40.00, with a median of US$37.00.
This is an external assessment, not a statement by Market Jury.
When does Kardigan report next?
The next earnings date is 10/11/2026.
Does Kardigan pay a dividend?
No, Kardigan currently does not pay a dividend.
Which stocks are comparable to Kardigan?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kardigan stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kardigan against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.